Novartis: positive data in ASCVD prevention
(CercleFinance.com) - Novartis reports positive initial results from the phase 3 'V-MONO' study, evaluating twice-yearly Leqvio for prevention in patients at low to moderate risk of developing atherosclerotic cardiovascular disease (ASCVD).
The product met its primary endpoints, demonstrating superiority in monotherapy over placebo and ezetimibe, with a clinically and statistically significant reduction in low-density lipoprotein cholesterol (LDL-C).
Novartis plans to present the results of this trial at an upcoming medical meeting and share them with regulatory agencies, including the US FDA.
This trial adds to the growing body of evidence for Leqvio across the ASCVD spectrum, as we strive to help more patients in need, its Medical Director said.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The product met its primary endpoints, demonstrating superiority in monotherapy over placebo and ezetimibe, with a clinically and statistically significant reduction in low-density lipoprotein cholesterol (LDL-C).
Novartis plans to present the results of this trial at an upcoming medical meeting and share them with regulatory agencies, including the US FDA.
This trial adds to the growing body of evidence for Leqvio across the ASCVD spectrum, as we strive to help more patients in need, its Medical Director said.
Copyright (c) 2024 CercleFinance.com. All rights reserved.